SCIB 1

Drug Profile

SCIB 1

Alternative Names: Cancer vaccine - Scancell; ImmunoBody melanoma vaccine - Scancell; Melanoma vaccine TRP2 gp100 - Scancell; SCIB-1

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Scancell
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 16 Sep 2016 Scancell plans a phase IIb trial for Malignant melanoma (Combination therapy) in USA
  • 06 Jul 2016 Efficacy data from a phase I/II trial in Malignant melanoma released by Scancell
  • 27 Jan 2016 Updated efficacy results from a phase I/II trial in Malignant melanoma (Late stage disease) released by Scancell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top